Citation Impact
Citing Papers
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist
2004 StandoutNobel
Comprehensive computational design of ordered peptide macrocycles
2017 StandoutScienceNobel
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
2008 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Immunotherapy of cancer in 2012
2012
Genome-wide Association of Hypoxia-inducible Factor (HIF)-1α and HIF-2α DNA Binding with Expression Profiling of Hypoxia-inducible Transcripts
2009 StandoutNobel
The impact of O2 availability on human cancer
2008
Hypoxia — a key regulatory factor in tumour growth
2002 Standout
Cancer statistics, 2020
2020 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
2007
EGFR Antagonists in Cancer Treatment
2008 Standout
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway
2004
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
Independent β-Arrestin2 and Gq/Protein Kinase Cζ Pathways for ERK Stimulated by Angiotensin Type 1A Receptors in Vascular Smooth Muscle Cells Converge on Transactivation of the Epidermal Growth Factor Receptor
2009 StandoutNobel
A view on drug resistance in cancer
2019 StandoutNature
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers
2003
The role of topotecan in the treatment of advanced cervical cancer
2003
Advances in Radiation Therapy for Brain Tumors
2007
Targeting hypoxia cell signaling for cancer therapy
2007
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Ovarian cancer
2014 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Cancer Metastasis: Building a Framework
2006 Standout
Cushing's syndrome
2015 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Radiation Therapy for Cushing's Disease: A Review
2002
Development trends for human monoclonal antibody therapeutics
2010
Ubiquitination of β-Arrestin Links Seven-transmembrane Receptor Endocytosis and ERK Activation
2007 StandoutNobel
The bone marrow niche for haematopoietic stem cells
2014 StandoutNature
Pathological Findings following Radiosurgery of Pituitary Adenomas
2007
Nicotine induces cell proliferation by -arrestin-mediated activation of Src and Rb-Raf-1 pathways
2006
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Exploiting tumour hypoxia in cancer treatment
2004 Standout
Four-and-a-Half LIM Domain Proteins Inhibit Transactivation by Hypoxia-inducible Factor 1
2012 StandoutNobel
Immunity, Inflammation, and Cancer
2010 Standout
The Efficacy of Linear Accelerator Radiosurgery in the Management of Patients with Cushing’s Disease
2004
Malignant Gliomas in Adults
2008 Standout
Radiosurgery for Cushing's disease after failed transsphenoidal surgery
2000
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
Radiation Therapy in the Multimodal Treatment Approach of Pituitary Adenoma
2002
Mesenchymal and haematopoietic stem cells form a unique bone marrow niche
2010 StandoutNature
Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting
2003
Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy
2006
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Cancer immunotherapy comes of age
2011 StandoutNature
Drug distribution in tumors: Mechanisms, role in drug resistance, and methods for modification
2007
Hsp70 and CHIP Selectively Mediate Ubiquitination and Degradation of Hypoxia-inducible Factor (HIF)-1α but Not HIF-2α
2009 StandoutNobel
A model for decision making for the use of radiotherapy in lung cancer
2003
Tumor-activated Prodrugs—A New Approach to Cancer Therapy
2004
Oxygen Sensing, Homeostasis, and Disease
2011 StandoutNobel
Optimization of the Auxiliary Ligand Shell of Cobalt(III)(8-hydroxyquinoline) Complexes as Model Hypoxia-Selective Radiation-Activated Prodrugs
2004
Lysosome-targeting chimaeras for degradation of extracellular proteins
2020 StandoutNatureNobel
An Alternative Form of Replication Protein A Expressed in Normal Human Tissues Supports DNA Repair
2009 StandoutNobel
Second Lung Cancers in Patients After Treatment for an Initial Lung Cancer
1998
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
2011 StandoutNobel
Spermidine/Spermine N1-Acetyltransferase-1 Binds to Hypoxia-inducible Factor-1α (HIF-1α) and RACK1 and Promotes Ubiquitination and Degradation of HIF-1α
2007 StandoutNobel
Drug Resistance and the Solid Tumor Microenvironment
2007 Standout
Replication protein A is an independent prognostic indicator with potential therapeutic implications in colon cancer
2007
Activation of 3-Amino-1,2,4-benzotriazine 1,4-Dioxide Antitumor Agents to Oxidizing Species Following Their One-Electron Reduction
2002
DNA-Targeted 1,2,4-Benzotriazine 1,4-Dioxides: Potent Analogues of the Hypoxia-Selective Cytotoxin Tirapazamine
2003
Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
2008 StandoutNobel
The Hypoxia-Activated ProDrug AQ4N Penetrates Deeply in Tumor Tissues and Complements the Limited Distribution of Mitoxantrone
2009
Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine.
2001
Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells
2005
Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling
2010
Physiology meets biophysics: Visualizing the interaction of hypoxia-inducible factor 1α with p300 and CBP
2002 StandoutNobel
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
2012 StandoutNobel
(18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer.
2001
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
β-Arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes
2006 StandoutNobel
Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer
2002
The role of radiotherapy in cancer treatment
2005 Standout
NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug.
2003
Cancer Genome Landscapes
2013 StandoutScience
Enzyme-Responsive Snap-Top Covered Silica Nanocontainers
2008 StandoutNobel
Hypoxia-Selective Antitumor Agents. 16. Nitroarylmethyl Quaternary Salts as Bioreductive Prodrugs of the Alkylating Agent Mechlorethamine
2001
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Tirapazamine: a hypoxia-activated topoisomerase II poison.
2002
Tobacco Use Outcomes Among Patients With Lung Cancer Treated for Nicotine Dependence
2002
Combinatorial Peptide Libraries: Mining for Cell-Binding Peptides
2013
Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
2001
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Oxygen Dependence of the Metabolic Activation and Cytotoxicity of Tirapazamine: Implications for Extravascular Transport andActivity in Tumors
2004
Immune Therapy for Cancer
2008
Coexistence of Quiescent and Active Adult Stem Cells in Mammals
2010 StandoutScience
Phase III Trial of Paclitaxel Plus Carboplatin With or Without Tirapazamine in Advanced Non–Small-Cell Lung Cancer: Southwest Oncology Group Trial S0003
2005
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Works of Gary Richardson being referenced
Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years.
1995
Reported management of lung cancer in Victoria in 1993: comparison with best practice
2000
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
2012
Initial clinical results of linac-based stereotactic radiosurgery and stereotactic radiotherapy for pituitary adenomas
1998
Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy
2002
Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group
2000
Smoking Cessation after Successful Treatment of Small-Cell Lung Cancer Is Associated with Fewer Smoking-related Second Primary Cancers
1993
Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer
2007 Standout
Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer
2001
Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
2011